PH12017501007B1 - Compositions comprising 2-((1-(2 - (4-fluorophenyl) -2- oxoethyl) piperidin-4-yl) methyl) isoindolin-1-one for treating schizophrenia - Google Patents
Compositions comprising 2-((1-(2 - (4-fluorophenyl) -2- oxoethyl) piperidin-4-yl) methyl) isoindolin-1-one for treating schizophreniaInfo
- Publication number
- PH12017501007B1 PH12017501007B1 PH1/2017/501007A PH12017501007A PH12017501007B1 PH 12017501007 B1 PH12017501007 B1 PH 12017501007B1 PH 12017501007 A PH12017501007 A PH 12017501007A PH 12017501007 B1 PH12017501007 B1 PH 12017501007B1
- Authority
- PH
- Philippines
- Prior art keywords
- isoindolin
- oxoethyl
- piperidin
- fluorophenyl
- methyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- RNRYULFRLCBRQS-UHFFFAOYSA-N roluperidone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 RNRYULFRLCBRQS-UHFFFAOYSA-N 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 abstract 2
- NZKANSJXJCILHS-UHFFFAOYSA-N 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3h-isoindol-1-one;dihydrate;hydrochloride Chemical compound O.O.Cl.C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 NZKANSJXJCILHS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086691P | 2014-12-02 | 2014-12-02 | |
| US201562248071P | 2015-10-29 | 2015-10-29 | |
| PCT/US2015/062985 WO2016089766A1 (en) | 2014-12-02 | 2015-11-30 | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12017501007A1 PH12017501007A1 (en) | 2017-12-18 |
| PH12017501007B1 true PH12017501007B1 (en) | 2024-07-03 |
Family
ID=54848909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2017/501007A PH12017501007B1 (en) | 2014-12-02 | 2015-11-30 | Compositions comprising 2-((1-(2 - (4-fluorophenyl) -2- oxoethyl) piperidin-4-yl) methyl) isoindolin-1-one for treating schizophrenia |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9458130B2 (enExample) |
| EP (2) | EP3227273B1 (enExample) |
| JP (4) | JP2018501217A (enExample) |
| KR (1) | KR102620681B1 (enExample) |
| CN (2) | CN107567444A (enExample) |
| AU (4) | AU2015355226B2 (enExample) |
| BR (1) | BR112017011555B1 (enExample) |
| CA (1) | CA2968977A1 (enExample) |
| CL (2) | CL2017001376A1 (enExample) |
| CO (1) | CO2017005498A2 (enExample) |
| DK (1) | DK3227273T3 (enExample) |
| EA (1) | EA201791226A1 (enExample) |
| ES (1) | ES2910528T3 (enExample) |
| HU (1) | HUE058212T2 (enExample) |
| IL (4) | IL280052B2 (enExample) |
| MX (1) | MX385586B (enExample) |
| MY (1) | MY185516A (enExample) |
| PE (1) | PE20171646A1 (enExample) |
| PH (1) | PH12017501007B1 (enExample) |
| PL (1) | PL3227273T3 (enExample) |
| PT (1) | PT3227273T (enExample) |
| SG (1) | SG11201704332YA (enExample) |
| TW (1) | TWI694069B (enExample) |
| UA (1) | UA122780C2 (enExample) |
| WO (1) | WO2016089766A1 (enExample) |
| ZA (1) | ZA201703481B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2910528T3 (es) | 2014-12-02 | 2022-05-12 | Minerva Neurosciences Inc | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia |
| EP3463356A1 (en) * | 2016-05-25 | 2019-04-10 | Minerva Neurosciences, Inc. | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| EP3641732A1 (en) * | 2017-06-21 | 2020-04-29 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| CN107721988A (zh) * | 2017-10-31 | 2018-02-23 | 无锡福祈制药有限公司 | 具有抗炎活性的异吲哚‑1‑酮类化合物 |
| BR112021002654A2 (pt) | 2018-08-21 | 2021-05-04 | Minerva Neurosciences, Inc. | uso de roluperidona para tratar sintomas e distúrbios negativos, aumentar a neuroplasticidade e promover neuroproteção |
| TWI841545B (zh) * | 2018-12-12 | 2024-05-11 | 日商田邊三菱製藥股份有限公司 | 耐胃性控制釋放經口劑型 |
| US12441701B2 (en) * | 2019-06-28 | 2025-10-14 | Tapi Czech Industries S.R.O. | Solid state forms of roluperidone and salts thereof |
| IL298323B2 (en) | 2020-05-20 | 2023-10-01 | Univ Illinois | A method for treating lysosomal storage disease using histatin peptides |
| US20230255953A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | Use of roluperidone in preventing relapse in schizophrenia patients |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0325063B1 (en) | 1988-01-21 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia |
| KR927002347A (ko) | 1989-10-27 | 1992-09-03 | 레이몬드 지. 아너 | (n-프탈이미도알킬) 피페리딘 |
| FR2797643B1 (fr) | 1999-08-17 | 2003-06-06 | Rhodia Chimie Sa | Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures |
| DE60129210T2 (de) * | 2000-02-29 | 2008-03-20 | Mitsubishi Pharma Corp. | Zyklische amid-derivate |
| CA2439097C (en) * | 2001-03-26 | 2010-10-12 | Novartis Ag | Pharmaceutical compositions |
| TW200716531A (en) | 2005-06-06 | 2007-05-01 | Merck Sharp & Dohme | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| CN103220910B (zh) * | 2010-07-20 | 2016-05-11 | 昔勒尼药品公司 | 使用环酰胺衍生物治疗精神分裂症的方法 |
| ES2914120T3 (es) | 2010-07-20 | 2022-06-07 | Minerva Neurosciences Inc | Procedimientos de uso de derivados de amida cíclicos para tratar trastornos mediados por el receptor sigma |
| EP2468264A1 (en) | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| MX2013010598A (es) * | 2011-03-17 | 2014-01-08 | Lupin Ltd | Composiciones farmaceuticas de liberacion controlada de inhibidor de recaptacion de serotonina selectivo. |
| US10179776B2 (en) * | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| ES2910528T3 (es) * | 2014-12-02 | 2022-05-12 | Minerva Neurosciences Inc | Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia |
| EP3463356A1 (en) | 2016-05-25 | 2019-04-10 | Minerva Neurosciences, Inc. | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| EP3641732A1 (en) | 2017-06-21 | 2020-04-29 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| BR112021002654A2 (pt) | 2018-08-21 | 2021-05-04 | Minerva Neurosciences, Inc. | uso de roluperidona para tratar sintomas e distúrbios negativos, aumentar a neuroplasticidade e promover neuroproteção |
-
2015
- 2015-11-30 ES ES15808314T patent/ES2910528T3/es active Active
- 2015-11-30 PT PT158083147T patent/PT3227273T/pt unknown
- 2015-11-30 AU AU2015355226A patent/AU2015355226B2/en active Active
- 2015-11-30 SG SG11201704332YA patent/SG11201704332YA/en unknown
- 2015-11-30 MX MX2017007065A patent/MX385586B/es unknown
- 2015-11-30 UA UAA201706785A patent/UA122780C2/uk unknown
- 2015-11-30 IL IL280052A patent/IL280052B2/en unknown
- 2015-11-30 WO PCT/US2015/062985 patent/WO2016089766A1/en not_active Ceased
- 2015-11-30 CN CN201580065471.3A patent/CN107567444A/zh active Pending
- 2015-11-30 EA EA201791226A patent/EA201791226A1/ru unknown
- 2015-11-30 CN CN202010012498.9A patent/CN111110677A/zh active Pending
- 2015-11-30 EP EP15808314.7A patent/EP3227273B1/en active Active
- 2015-11-30 PE PE2017000948A patent/PE20171646A1/es unknown
- 2015-11-30 PH PH1/2017/501007A patent/PH12017501007B1/en unknown
- 2015-11-30 TW TW104139904A patent/TWI694069B/zh active
- 2015-11-30 MY MYPI2017701998A patent/MY185516A/en unknown
- 2015-11-30 KR KR1020177018088A patent/KR102620681B1/ko active Active
- 2015-11-30 EP EP22155504.8A patent/EP4063357A1/en active Pending
- 2015-11-30 PL PL15808314T patent/PL3227273T3/pl unknown
- 2015-11-30 CA CA2968977A patent/CA2968977A1/en active Pending
- 2015-11-30 US US14/954,264 patent/US9458130B2/en active Active
- 2015-11-30 IL IL313572A patent/IL313572A/en unknown
- 2015-11-30 HU HUE15808314A patent/HUE058212T2/hu unknown
- 2015-11-30 BR BR112017011555-7A patent/BR112017011555B1/pt active IP Right Grant
- 2015-11-30 DK DK15808314.7T patent/DK3227273T3/da active
- 2015-11-30 JP JP2017529388A patent/JP2018501217A/ja active Pending
- 2015-11-30 IL IL301320A patent/IL301320B2/en unknown
-
2016
- 2016-09-28 US US15/278,421 patent/US9730920B2/en active Active
-
2017
- 2017-05-17 IL IL252347A patent/IL252347B/en active IP Right Grant
- 2017-05-19 ZA ZA2017/03481A patent/ZA201703481B/en unknown
- 2017-05-30 CL CL2017001376A patent/CL2017001376A1/es unknown
- 2017-05-31 CO CONC2017/0005498A patent/CO2017005498A2/es unknown
- 2017-07-17 US US15/651,065 patent/US10258614B2/en active Active
-
2019
- 2019-03-01 US US16/290,234 patent/US10799493B2/en active Active
-
2020
- 2020-06-26 AU AU2020204286A patent/AU2020204286B2/en active Active
- 2020-07-06 JP JP2020116157A patent/JP7069253B2/ja active Active
- 2020-09-11 US US17/017,816 patent/US20210228561A1/en not_active Abandoned
-
2021
- 2021-01-07 CL CL2021000044A patent/CL2021000044A1/es unknown
- 2021-09-10 AU AU2021229240A patent/AU2021229240B2/en active Active
-
2022
- 2022-05-02 JP JP2022076280A patent/JP2022105159A/ja active Pending
-
2023
- 2023-02-17 US US18/111,072 patent/US20230201184A1/en not_active Abandoned
- 2023-11-01 AU AU2023258386A patent/AU2023258386B2/en active Active
-
2024
- 2024-10-02 JP JP2024173051A patent/JP2025004090A/ja active Pending
- 2024-11-27 US US18/961,748 patent/US20250195494A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501007B1 (en) | Compositions comprising 2-((1-(2 - (4-fluorophenyl) -2- oxoethyl) piperidin-4-yl) methyl) isoindolin-1-one for treating schizophrenia | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| PH12016501379A1 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| WO2015200680A3 (en) | Prmt5 inhibitors and uses thereof | |
| PH12016501972A1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| MX381342B (es) | Compuestos terapeuticos inhibidores. | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| IL246875A0 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
| PH12020551586A1 (en) | Oxysterols and methods of use thereof | |
| EP4088724C0 (en) | ACETYLCHOLINESTERASE INHIBITORS FOR THE ORAL TREATMENT OF DERMATOLOGICAL CONDITIONS | |
| HRP20181698T1 (hr) | 2-amino-6-(difluormetil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridini kao inhibitori bace1 | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| IN2014MU00675A (enExample) | ||
| EP2948441A4 (en) | PROCESS FOR PREPARATION OF 1- (4- (4- (3,4-DICHLOR-2-FLUORO-PHENYL AMINO) -7-METHOXYCHINAZOLINE-6-YLOXY) PIPERIDIN-1-YL) PROP-2-EN-1-ON | |
| MX389403B (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo | |
| HK1227027A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer’s disease |